Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong · Delayed Price · Currency is HKD 43.32
+1.62 (3.88%)
Nov 10, 2026, 4:08 PM HKT
HKG:2315 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 909.1 | 1,585 | 403.85 | 417.66 | 626.62 | 466.45 |
Short-Term Investments | - | 10.53 | 7.25 | 7.89 | 9.15 | 106.98 |
Trading Asset Securities | 80.1 | - | - | 8.49 | 8.2 | - |
Cash & Short-Term Investments | 989.2 | 1,596 | 411.1 | 434.04 | 643.97 | 573.42 |
Cash Growth | 181.34% | 288.15% | -5.29% | -32.60% | 12.30% | -40.11% |
Accounts Receivable | 313.71 | 300.31 | 229.61 | 142.38 | 107.68 | 103.09 |
Other Receivables | 17.63 | 13.19 | 5.88 | 6.04 | 4.17 | 14.96 |
Receivables | 331.35 | 313.5 | 235.48 | 148.43 | 111.85 | 118.05 |
Inventory | 246.41 | 15.22 | 5.39 | 9.9 | 23.73 | 21.65 |
Other Current Assets | 123.68 | 224.38 | 164.57 | 130.69 | 139.74 | 161.11 |
Total Current Assets | 1,691 | 2,149 | 816.54 | 723.05 | 919.3 | 874.24 |
Property, Plant & Equipment | 1,713 | 1,366 | 1,349 | 1,451 | 1,599 | 1,391 |
Long-Term Investments | 193.95 | 192.06 | 222.61 | 241.24 | 250.81 | 9.69 |
Other Intangible Assets | 49.88 | 13.36 | 20.67 | 28.13 | 30.65 | 6.06 |
Long-Term Deferred Tax Assets | 2.78 | 0.99 | 0.96 | - | - | - |
Other Long-Term Assets | 36.77 | 3.34 | 5.06 | 6.16 | - | 21.86 |
Total Assets | 3,782 | 3,724 | 2,415 | 2,449 | 2,800 | 2,303 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 124.13 | 135.83 | 115.48 | 175.23 | 146.19 | 102.44 |
Accrued Expenses | 36.97 | 79.8 | 38.97 | 27.89 | 51.62 | 53.66 |
Current Portion of Long-Term Debt | 181.54 | 195.42 | 208.14 | 176.84 | 126.67 | - |
Current Portion of Leases | - | 31.94 | 17.86 | 26.36 | 44.94 | 26.9 |
Current Income Taxes Payable | 6.99 | 2 | 4.01 | 4.51 | 4.2 | 5.02 |
Current Unearned Revenue | 144.79 | 103.76 | 102.19 | 69.22 | 56.38 | 61.58 |
Other Current Liabilities | 78.93 | 381.56 | 48.26 | 97.56 | 176.06 | 196.96 |
Total Current Liabilities | 573.34 | 930.31 | 534.91 | 577.62 | 606.05 | 446.56 |
Long-Term Debt | 229.55 | 192.82 | 193.84 | 173.91 | 52.17 | - |
Long-Term Leases | 398.82 | 163.91 | 150.45 | 167.01 | 191.51 | 62.9 |
Long-Term Unearned Revenue | 80.44 | 82.54 | 84.9 | 87.07 | 89.93 | 92.8 |
Long-Term Deferred Tax Liabilities | - | - | - | 1.9 | - | - |
Other Long-Term Liabilities | - | 175.34 | 612.62 | 651.48 | 709.36 | 448.55 |
Total Liabilities | 1,282 | 1,545 | 1,577 | 1,659 | 1,649 | 1,051 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 446.9 | 446.9 | 399.4 | 399.4 | 399.4 | 374.93 |
Additional Paid-In Capital | 3,354 | 3,088 | 1,992 | 1,992 | 1,992 | 1,516 |
Retained Earnings | -1,261 | -1,573 | -1,754 | -1,787 | -1,404 | -802.32 |
Treasury Stock | -44.21 | -45.35 | -32.77 | -27.18 | -18.99 | - |
Comprehensive Income & Other | -0.49 | 258.41 | 229.3 | 209.09 | 178.32 | 159.03 |
Total Common Equity | 2,496 | 2,175 | 834.06 | 785.89 | 1,146 | 1,247 |
Minority Interest | 4.54 | 4.55 | 4.55 | 4.55 | 4.55 | 4.76 |
Shareholders' Equity | 2,500 | 2,179 | 838.6 | 790.44 | 1,151 | 1,252 |
Total Liabilities & Equity | 3,782 | 3,724 | 2,415 | 2,449 | 2,800 | 2,303 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 809.91 | 584.09 | 570.28 | 544.11 | 415.28 | 89.8 |
Net Cash (Debt) | 179.29 | 1,012 | -159.18 | -110.07 | 228.69 | 483.62 |
Net Cash Growth | - | - | - | - | -52.71% | -44.82% |
Net Cash Per Share | 0.41 | 2.53 | -0.40 | -0.28 | 0.60 | 1.33 |
Filing Date Shares Outstanding | 446.9 | 446.9 | 399.4 | 399.4 | 399.4 | 396.69 |
Total Common Shares Outstanding | 446.9 | 446.9 | 399.4 | 399.4 | 399.4 | 374.93 |
Working Capital | 1,117 | 1,218 | 281.62 | 145.43 | 313.25 | 427.68 |
Book Value Per Share | 5.58 | 4.87 | 2.09 | 1.97 | 2.87 | 3.33 |
Tangible Book Value | 2,446 | 2,162 | 813.39 | 757.76 | 1,116 | 1,241 |
Tangible Book Value Per Share | 5.47 | 4.84 | 2.04 | 1.90 | 2.79 | 3.31 |
Machinery | - | 1,568 | 1,502 | 1,437 | 1,208 | 1,107 |
Construction In Progress | - | 49.1 | 1.9 | 5.19 | 268.29 | 181.96 |
Leasehold Improvements | - | 233.17 | 232.8 | 240.53 | 161.75 | 166.43 |